What to Know About the USPTO Access to Relevant Prior Art Initiative

The USPTO recently announced its Relevant Prior Art (RPA) Initiative, seeking to leverage electronic resources to improve an examiner’s access to relevant information from applicant’s other related applications.  These resources may include related U.S. applications, international applications under the PCT, and counterpart foreign applications by the same applicant. What are the advantages? Simplifies application process for applicant Speeds up examination process Increases efficiency of prosecution procedures Improves prosecution quality What you should be aware of Notification of application included in RPA initiative.  You will receive a Notice of Imported Citations informing you of your application’s inclusion in the Initiative and

Continue reading »

MaxVal Publishes Advanced CRISPR-Cas9 Report

Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research.  The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research.  The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers. MaxVal’s CRISPR report is now available through Patent LiveScape™, an analysis and reporting service that provides clients with interactive reports which extract

Continue reading »

Hot Topics in Tech | October 2018 Newsletter | Maxval

This article provides a brief overview of the role of the autonomous nervous system in managing hypertension and describes various techniques related to neurostimulation. Patents revealing various energy-based techniques for neurostimulation, and devices related thereto which are available in the market are also presented. It also highlights various sectors where artificial intelligence (AI) powered robots are employed in, and focuses on two major industries a) agriculture and b) retail. Key players in this technology along with the tech categorization of their patent portfolio are charted out, and some exemplary patents in both agriculture and retail are illustrated.

Continue reading »

Hot Topics in Tech | September 2018 Newsletter | Maxval

This issue covers cardiovascular diseases and discloses the technological categories and products related to the use of renal denervation approach for managing hypertension. It also talks about the three main categories of Artificial Intelligence namely Artificial Narrow Intelligence (ANI), Artificial General Intelligence (AGI), and Artificial Super Intelligence (ASI). They influence human life in the form of automated cars, virtual assistants, image recognition software, robotics, games, life science and so on. Read more on this report.

Continue reading »

Hot Topics in Tech | August 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some insights about the company alongwith a quick run-through of the firm’s recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification. We have also discussed about Walmart, who aims to venture into transportation and logistics markets through a methodology (recently filed for patent) by

Continue reading »

Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA’s approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018. We have

Continue reading »

Technology Landscape Study on CRISPR-Cas9

Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives. The objective of this study is to explore the market and patenting activity in CRISPR-Cas9 gene editing technology. This study considers issued patents and pending published applications related to CRISPR-Cas9 published since January 1, 2007. Search strategies using various combinations of keywords, classification codes, and prominent assignees resulted in more

Continue reading »

Recent advances in Diabetes Management | April 2018 Newsletter | MaxVal

The article addresses Medtronic’s recent FDA approval of the Guardian™ Connect Continuous Glucose Monitoring (CGM) system. A brief overview of all the clinical studies related to CGM has been presented. It also analyzes the recent findings on a microneedle system for non-invasive insulin delivery. A birds-eye view of patent filings related to microneedles for insulin delivery, with a focus on global players is presented.

Continue reading »

Acquisition and Predictive Analysis

It’s been a busy year for mergers and acquisitions, with a number of billion dollar deals that happened. We tracked and analyzed over 700 Mergers & Acquisitions that occurred in 2017 and extracted the 20 largest deals across 9 industries, valued above $5 B. $274.9B in large M&A transactions took place in 2017. 42% of the transactions occurred in the Medical/Pharma Sector totaling $86.6 B across 8 events. 21% of the transactions occurred in the Energy Sector totaling $28.3 B across 4 events. The largest acquisition in the most active sector: Medical equipment/Pharma was J&J | Actelion at $30B. The largest acquisition

Continue reading »